Cerebrospinal-fluid biomarkers for predicting phenoconversion in patients with isolated rapid-eye movement sleep behavior disorder
SLEEP · 2024
DOI: 10.1093/sleep/zsad198 ↗Kurz gefasst
Fachartikel in der Zeitschrift SLEEP, 2024. Verfasst von Mariana Fernandes und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Systems Medicine, University of Rome 'Tor Vergata", Rome, Italy. Hauptthemen laut MEDLINE: Synucleinopathies, REM Sleep Behavior Disorder, Parkinson Disease. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 61 Literaturangaben.
Abstract (Originalsprache)
Study Objectives Patients with isolated rapid-eye-movement sleep behavior disorder (iRBD) have an increased risk of developing neurodegenerative diseases. This study assessed cerebrospinal-fluid (CSF) biomarkers of neurodegeneration and blood-brain barrier (BBB) alteration in patients with iRBD compared to controls and ascertain whether these biomarkers may predict phenoconversion to alpha-synucleinopathies (Parkinson’s Disease (PD), Dementia with Lewy bodies (DLB), Multiple System Atrophy (MSA)).
Methods
Patients and controls underwent between 2012 and 2016 a neurological assessment, a lumbar puncture for CSF biomarker analysis (β-amyloid42 - Aβ42; total-tau, and phosphorylated tau), and BBB alteration (CSF/serum albumin ratio). All patients with iRBD were followed until 2021 and then classified into patients who converted to alpha-synucleinopathies (iRBD converters, cRBD) or not (iRBD non-converters, ncRBD).
Results
Thirty-four patients with iRBD (mean age 67.12 ± 8.14) and 33 controls (mean age 64.97 ± 8.91) were included. At follow-up (7.63 ± 3.40 years), eight patients were ncRBD and 33 patients were cRBD: eleven converted to PD, 10 to DLB, and two to MSA. Patients with iRBD showed lower CSF Aβ42 levels and higher CSF/serum albumin ratio than controls. Cox regression analysis showed that the phenoconversion rate increases with higher motor impairment (hazard ratio [HR] = 1.23, p = 0.032). CSF Aβ42 levels predicted phenoconversion to DLB (HR = 0.67, p = 0.038) and BBB alteration predicted phenoconversion to PD (HR = 1.20, p = 0.038).
Discussion
This study showed that low CSF Aβ42 levels and high BBB alteration may predict the phenoconversion to DLB and PD in patients with iRBD, respectively. These findings highlight the possibility to discriminate phenoconversion in iRBD patients through CSF biomarkers; however, further studies are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Systems Medicine, University of Rome 'Tor Vergata", Rome, Italy.
- Sleep Medicine Centre, Neurology Unit, University Hospital "Tor Vergata", Rome, Italy.
- Department of Medicine, Neurology Clinic, University Hospital of Perugia, Italy.
- Department of Clinical Biochemistry and Molecular Biology, University of Rome "Tor Vergata", Rome, Italy.
ORCID-Profile: Paolo Eusebi, Claudio Liguori
Zitieren
APA
Fernandes, M., Maio, S., Eusebi, P., Placidi, F., Izzi, F., Spanetta, M., De Masi, C., Lupo, C., Calvello, C., Nuccetelli, M., Bernardini, S., Mercuri, N. B., & Liguori, C. (2024). Cerebrospinal-fluid biomarkers for predicting phenoconversion in patients with isolated rapid-eye movement sleep behavior disorder. SLEEP. https://doi.org/10.1093/sleep/zsad198
Vancouver
Fernandes M, Maio S, Eusebi P, Placidi F, Izzi F, Spanetta M, et al. Cerebrospinal-fluid biomarkers for predicting phenoconversion in patients with isolated rapid-eye movement sleep behavior disorder. SLEEP. 2024. doi:10.1093/sleep/zsad198
BibTeX
@article{Fernandes2024,
author = {Fernandes, Mariana and Maio, Silvia and Eusebi, Paolo and Placidi, Fabio and Izzi, Francesca and Spanetta, Matteo and De Masi, Claudia and Lupo, Clementina and Calvello, Carmen and Nuccetelli, Marzia and Bernardini, Sergio and Mercuri, Nicola Biagio and Liguori, Claudio},
title = {Cerebrospinal-fluid biomarkers for predicting phenoconversion in patients with isolated rapid-eye movement sleep behavior disorder},
journal = {SLEEP},
year = {2024},
doi = {10.1093/sleep/zsad198}
}
EUVIMED